EP Patent
EP3592355B1 — Kx2-391/kx-01 for use in the treatment of actinic keratosis
Assigned to Atnx Spv LLC · Expires 2025-12-10 · 0y expired
What this patent protects
Patent listed against Klisyri.
Drugs covered by this patent
- Klisyri (TIRBANIBULIN) · Almirall
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.